Influencing factors for the prognosis of patients with drug-induced liver injury and establishment of a nomogram model

Shimei WANG; Shuai JIN; Junru LI; Na WANG; Yan CHEN; Ying CUI; Mingming MA; Xiaoli HU

doi:10.12449/JCH240320

Volume 40 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(3): 562-567

PDF( 852 KB)

Influencing factors for the prognosis of patients with drug-induced liver injury and establishment of a nomogram model

DOI: 10.12449/JCH240320

Shimei WANG^1a,
Shuai JIN²,
Junru LI^1a,
Na WANG^1b,
Yan CHEN^1a,
Ying CUI^1a,
Mingming MA^1b,
Xiaoli HU^{1a
,
,
,}

1a.
Department of Infectious Diseases，Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology，Harbin 150036，China
1b.
Department of Pharmacy，Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology，Harbin 150036，China
2.
School of Big Health，Guizhou Medical University，Guiyang 550025，China

Research funding:

Scientific Research Project of Health Commission of Heilongjiang Province (20210303080081);

Heilongjiang Postdoctoral Scientific Research Development Fund (LBH-Q20056)

More Information

Corresponding author: HU Xiaoli， huxiaoli1976@163.com （ORCID： 0000-0002-4615-1299）
Received Date: 2023-05-30
Accepted Date: 2023-07-12
Published Date: 2024-03-20

Abstract

Abstract

Objective To investigate the influencing factors for the clinical outcome of patients with drug-induced liver injury （DILI）， and to establish a nomogram prediction model for validation. Methods A retrospective analysis was performed for the general information and laboratory data of 188 patients with DILI who were admitted to Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology from January 2017 to December 2022， and according to their clinical outcome， they were divided into good outcome group with 146 patients and poor outcome group with 42 patients. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. Univariate and multivariate Logistic regression analyses were used to investigate the independent influencing factors for the clinical outcome of DILI patients. R Studio 4.1.2 software was used to establish a nomogram model， and calibration curve， receiver operating characteristic （ROC） curve， and decision curve analysis （DCA） were used to perform internal validation. Results The univariate Logistic regression analysis showed that liver biopsy for the diagnosis of DILI， platelet count， cholinesterase， albumin， prothrombin time activity， IgM， and IgG were associated with adverse outcomes in patients with DILI. The multivariate Logistic regression analysis showed that liver biopsy for the diagnosis of DILI （odds ratio ［OR］=0.072， 95% confidence interval ［CI］： 0.022‍ ‍—‍ ‍0.213， P<0.001）， clinical classification （OR=0.463， 95%CI： 0.213‍ ‍—‍ ‍0.926， P=0.039）， alanine aminotransferase （OR=0.999， 95%CI： 0.998‍ ‍—‍ ‍1.000， P=0.025）， prothrombin time activity （OR=0.973， 95%CI： 0.952‍ ‍—‍ ‍0.993， P=0.011）， and IgM （OR=1.456， 95%CI： 1.082‍ ‍—‍ ‍2.021， P=0.015） were independent influencing factors for clinical outcome in patients with DILI. The nomogram prediction model was established， and after validation， the calibration curve was close to the reference curve. The area under the ROC curve was 0.829， and the DCA curve showed that the model had good net clinical benefit. Conclusion The nomogram prediction model established in this study has good clinical calibration， discriminative ability， and application value in evaluating the clinical outcome of patients with DILI.
- Chemical and Drug Induced Liver Injury,
- Prognosis,
- Nomograms

FullText(HTML)

References(11)

References

[1]	KAPLOWITZ N. Idiosyncratic drug hepatotoxicity[J]. Nat Rev Drug Discov, 2005, 4( 6): 489- 499. DOI: 10.1038/nrd1750.
[2]	NAVARRO VJ, SENIOR JR. Drug-related hepatotoxicity[J]. N Engl J Med, 2006, 354( 7): 731- 739. DOI: 10.1056/NEJMra052270.
[3]	CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109( 7): 950- 966. DOI: 10.1038/ajg.2014.131.
[4]	Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury(2019)[J]. Chin J Gen Pract, 2020, 19( 10): 868- 875. DOI: 10.3760/cma.j.cn114798-20200812-00900. 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 药物性肝损伤基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19( 10): 868- 875. DOI: 10.3760/cma.j.cn114798-20200812-00900.
[5]	BALACHANDRAN VP, GONEN M, SMITH JJ, et al. Nomograms in oncology: More than meets the eye[J]. Lancet Oncol, 2015, 16( 4): e173- e180. DOI: 10.1016/S1470-2045(14)71116-7.
[6]	PARK SY. Nomogram: An analogue tool to deliver digital knowledge[J]. J Thorac Cardiovasc Surg, 2018, 155( 4): 1793. DOI: 10.1016/j.jtcvs.2017.12.107.
[7]	IASONOS A, SCHRAG D, RAJ GV, et al. How to build and interpret a nomogram for cancer prognosis[J]. J Clin Oncol, 2008, 26( 8): 1364- 1370. DOI: 10.1200/JCO.2007.12.9791.
[8]	CHEN S, YANG CQ. Drug-induced liver injury: Advances and confusions in treatment[J]. J Clin Hepatol, 2021, 37( 11): 2505- 2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001. 陈帅, 杨长青. 药物性肝损伤治疗的进展与困惑[J]. 临床肝胆病杂志, 2021, 37( 11): 2505- 2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001.
[9]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70( 6): 1222- 1261. DOI: 10.1016/j.jhep.2019.02.014.
[10]	BONKOVSKY HL, KLEINER DE, GU JZ, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements[J]. Hepatology, 2017, 65( 4): 1267- 1277. DOI: 10.1002/hep.28967.
[11]	JEONG R, LEE YS, SOHN C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury[J]. Scand J Gastroenterol, 2015, 50( 4): 439- 446. DOI: 10.3109/00365521.2014.958094.

Relative Articles

[1]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
[2]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[3]	Bin YAN, Gexi CAO, Yanru DENG, Ying LI, Zhanjun DONG, Wanjun BAI. Effect of amlodipine and levamlodipine on the pharmacokinetics of lenvatinib in rats and related mechanisms[J]. Journal of Clinical Hepatology, 2024, 40(11): 2246-2252. doi: 10.12449/JCH241118
[4]	Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
[5]	Wei SUN, Xiaoyan DING, Jinglong CHEN. Efficacy and safety of anti-PD-1 monoclonal antibody combined with sorafenib or lenvatinib in treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(5): 975-981. doi: 10.12449/JCH240517
[6]	Hong NIE, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of tyrosine kinase inhibitor combined with immune checkpoint inhibitor as the second-line therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(8): 1620-1626. doi: 10.12449/JCH240818
[7]	Changwang ZHANG, Ninghan WU, Cong WANG, Zheng ZHENG, Siming GAO, Changpeng ZOU, Sujing ZHANG, Na LI. Efficacy and safety of cryoablation combined with Camrelizumab monoclonal antibody in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1169-1174. doi: 10.12449/JCH240616
[8]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[9]	Xingshu ZHU, Pengfei CHEN, Mengfan ZHANG, Fangzheng LI, Jinwei CHEN, Wenguang ZHANG, Xuhua DUAN, Jianzhuang REN, Xinwei HAN. Efficacy and safety of ¹²⁵I intraluminal irradiation combined with lenvatinib in treatment of progressive extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(10): 2406-2412. doi: 10.3969/j.issn.1001-5256.2023.10.019
[10]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[11]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[12]	Xiaoyan DING, Wei SUN, Yanjun SHEN, Ying TENG, Yawen XU, Wendong LI, Jinglong CHEN. Efficacy and safety of lenvatinib combined with sintilimab as the second-line therapy for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(8): 1813-1818. doi: 10.3969/j.issn.1001-5256.2022.08.018
[13]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[14]	Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN. Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor[J]. Journal of Clinical Hepatology, 2022, 38(6): 1323-1327. doi: 10.3969/j.issn.1001-5256.2022.06.020
[15]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[16]	Xiaoquan JI, Aimin ZHANG, Tao ZHANG, Wengang LI, Weiping HE, Jing SUN, Xuezhang DUAN. Efficacy and safety of sequential lenvatinib therapy after stereotactic body radiotherapy in treatment of advanced primary liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2120-2124. doi: 10.3969/j.issn.1001-5256.2021.09.023
[17]	Ying TENG, Xiaoyan DING, Wendong LI, Jinglong CHEN. Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events[J]. Journal of Clinical Hepatology, 2021, 37(3): 606-610. doi: 10.3969/j.issn.1001-5256.2021.03.020
[18]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043
[19]	Li GuangXin, Zhang Yu, Yang YanMei, Wang Yi, Li Gong. Efficacy and safety of lenvatinib for unresectable,advanced hepatocellular carcinoma in a real-world setting[J]. Journal of Clinical Hepatology, 2020, 36(10): 2266-2269. doi: 10.3969/j.issn.1001-5256.2020.10.021
[20]	Ni MingLi. Clinical effect of transcatheter arterial chemoembolization combined with argon-helium cryoablation in patients with advanced unresectable primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 99-102. doi: 10.3969/j.issn.1001-5256.2015.01.021

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 蒋伊雯，戴正皓，郭航，陆雨婷，钟李长，梁涛. 剪切波弹性成像超声在男性前尿道狭窄中的应用. 中国医师杂志. 2024(12): 1808-1811 .
Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (437) PDF downloads(61)

Influencing factors for the prognosis of patients with drug-induced liver injury and establishment of a nomogram model

DOI: 10.12449/JCH240320

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Influencing factors for the prognosis of patients with drug-induced liver injury and establishment of a nomogram model

DOI: 10.12449/JCH240320

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content